Patents by Inventor Benjamin W. Li

Benjamin W. Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
    Patent number: 10028911
    Abstract: Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a Cmax of MTX between 5% and 50% of the Cmax of an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. Also disclosed are methods of treating autoimmune diseases and cancer by administering these formulations of MTX.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 24, 2018
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Louie Daniel Garcia, Lois Gibson, William Joseph Lambert, Benjamin W. Li, Liangjin Zhu
  • Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
    Patent number: 9770414
    Abstract: Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a Cmax of MTX between 5% and 50% of the Cmax of an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. Also disclosed are methods of treating autoimmune diseases and cancer by administering these formulations of MTX.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: September 26, 2017
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Louie Daniel Garcia, Lois Gibson, William Lambert, Benjamin W. Li, Liangjin Zhu
  • SUSTAINED RELEASE FORMULATION OF METHOTREXATE AS A DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD) AND AN ANTI-CANCER AGENT
    Publication number: 20110280932
    Abstract: Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a Cmax of MTX between 5% and 50% of the Cmax of an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. Also disclosed are methods of treating autoimmune diseases and cancer by administering these formulations of MTX.
    Type: Application
    Filed: October 28, 2010
    Publication date: November 17, 2011
    Applicant: PACIRA PHARMACEUTICALS, INC.
    Inventors: Louie Daniel Garcia, Lois Gibson, William Lambert, Benjamin W. Li, Liangjin Zhu